Comparative Pharmacology
Head-to-head clinical analysis: GO EVAC versus OSMOPREP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GO EVAC versus OSMOPREP.
GO-EVAC vs OSMOPREP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promotes gastrointestinal motility by acting as a stimulant laxative, likely through direct irritation of the colonic mucosa and possibly via local effects on enteric neurons.
Osmotic laxative. Sodium phosphate draws water into the intestinal lumen via osmotic gradient, increasing intraluminal pressure and stimulating peristalsis.
10 mg orally once daily, with or without food.
3 tablets orally in the evening before colonoscopy, followed by 3 tablets the next morning, each dose with at least 1.5 L of clear liquids; maximum 6 tablets total.
None Documented
None Documented
4.5-6 hours in healthy volunteers; prolonged to 10-14 hours in elderly patients and those with moderate renal impairment (CrCl 30-50 mL/min).
The terminal elimination half-life of the absorbed fraction is approximately 2.7 hours. This short half-life indicates rapid renal clearance of the small amount absorbed; however, the clinical effect (bowel cleansing) is independent of systemic elimination.
Primarily renal; approximately 60% eliminated unchanged in urine within 24 hours, with 20% as metabolites. Biliary/fecal excretion accounts for 15-20%, and the remainder is metabolized via glucuronidation.
Osmoprep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) is not significantly absorbed systemically; the majority of the administered dose remains in the gastrointestinal tract and is eliminated in the feces. Less than 1% of the dose is absorbed and subsequently excreted unchanged in the urine via renal filtration.
Category C
Category C
Osmotic Laxative
Osmotic Laxative